Appili Therapeutics is currently leading several anti-infective programs, at various stages of development. These programs are designed to address the existing critical unmet medical needs of patients with infectious disease, providing novel therapeutics to treat even the most drug-resistant infections.
Appili is developing a small molecule antibiotic to treat nosocomial infections caused by drug-resistant Gram-negative bacteria. The antibiotic, ATI-1503, inhibits bacterial translation by binding to the 30S ribosomal subunit. It has a unique binding site and mechanism of action, representing a novel class of antibiotic.
Appili is repurposing an existing antibiotic through the FDA’s 505(b)(2) new drug application process, an appealing regulatory strategy that helps avoid unnecessary duplication of studies already performed on the previously approved drug. This antibiotic, ATI-1501, will address an identified unmet medical need. The program is currently confidential, with the target and program details to be announced upon entering the clinic in early 2017.